Serveur d'exploration H2N2

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus : Identification of aminoadamantane derivatives bearing two pharmacophoric amine groups

Identifieur interne : 000070 ( PascalFrancis/Checkpoint ); précédent : 000069; suivant : 000071

Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus : Identification of aminoadamantane derivatives bearing two pharmacophoric amine groups

Auteurs : George Stamatiou [Grèce] ; Antonios Kolocouris [Grèce] ; Nicolas Kolocouris [Grèce] ; George Fytas [Grèce] ; George B. Foscolos [Grèce] ; Johan Neyts [Belgique] ; Erik De Clercq [Belgique]

Source :

RBID : Pascal:01-0423706

Descripteurs français

English descriptors

Abstract

The 3(2-adamantyl)pyrrolidines 8a g, 14 were synthesized and evaluated for activity against influenza A virus. The parent N H compound 14 was several times more active than amantadine against H2N2 and H3N2 influenza A virus. The combined use of NMR spectroscopy and computational chemistry showed that the conformation around the pyrrolidine-adamantyl carbon carbon bond is trans and the pyrrolidine heterocycle has an envelope conformation with C-2 out of the plane of the other ring atoms. N-Dialkylaminoethyl substitution of compound 14 resulted in the potent diamine analogues 8e,f,g. Interestingly, their lactam amine precursors were also active. Compounds 8e,f,g are the first adamantane derivatives, bearing two amine groups, reported to be active against influenza A virus.


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:01-0423706

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus : Identification of aminoadamantane derivatives bearing two pharmacophoric amine groups</title>
<author>
<name sortKey="Stamatiou, George" sort="Stamatiou, George" uniqKey="Stamatiou G" first="George" last="Stamatiou">George Stamatiou</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>School of Pharmacy, Department of Pharmaceutical Chemistry, University of Athens, Panepistimioupoli-Zografou</s1>
<s2>15771 Athens</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<placeName>
<settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kolocouris, Antonios" sort="Kolocouris, Antonios" uniqKey="Kolocouris A" first="Antonios" last="Kolocouris">Antonios Kolocouris</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>School of Pharmacy, Department of Pharmaceutical Chemistry, University of Athens, Panepistimioupoli-Zografou</s1>
<s2>15771 Athens</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<placeName>
<settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kolocouris, Nicolas" sort="Kolocouris, Nicolas" uniqKey="Kolocouris N" first="Nicolas" last="Kolocouris">Nicolas Kolocouris</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>School of Pharmacy, Department of Pharmaceutical Chemistry, University of Athens, Panepistimioupoli-Zografou</s1>
<s2>15771 Athens</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<placeName>
<settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Fytas, George" sort="Fytas, George" uniqKey="Fytas G" first="George" last="Fytas">George Fytas</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>School of Pharmacy, Department of Pharmaceutical Chemistry, University of Athens, Panepistimioupoli-Zografou</s1>
<s2>15771 Athens</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<placeName>
<settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Foscolos, George B" sort="Foscolos, George B" uniqKey="Foscolos G" first="George B." last="Foscolos">George B. Foscolos</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>School of Pharmacy, Department of Pharmaceutical Chemistry, University of Athens, Panepistimioupoli-Zografou</s1>
<s2>15771 Athens</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<placeName>
<settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Neyts, Johan" sort="Neyts, Johan" uniqKey="Neyts J" first="Johan" last="Neyts">Johan Neyts</name>
<affiliation wicri:level="4">
<inist:fA14 i1="02">
<s1>Rega Institute for Medical Research, Katholieke Universiteit Leuven</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName>
<region type="province" nuts="2">Province du Brabant flamand</region>
<settlement type="city">Louvain</settlement>
</placeName>
<orgName type="university">Katholieke Universiteit Leuven</orgName>
</affiliation>
</author>
<author>
<name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
<affiliation wicri:level="4">
<inist:fA14 i1="02">
<s1>Rega Institute for Medical Research, Katholieke Universiteit Leuven</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName>
<region type="province" nuts="2">Province du Brabant flamand</region>
<settlement type="city">Louvain</settlement>
</placeName>
<orgName type="university">Katholieke Universiteit Leuven</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">01-0423706</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 01-0423706 INIST</idno>
<idno type="RBID">Pascal:01-0423706</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000071</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000003</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000070</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000070</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus : Identification of aminoadamantane derivatives bearing two pharmacophoric amine groups</title>
<author>
<name sortKey="Stamatiou, George" sort="Stamatiou, George" uniqKey="Stamatiou G" first="George" last="Stamatiou">George Stamatiou</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>School of Pharmacy, Department of Pharmaceutical Chemistry, University of Athens, Panepistimioupoli-Zografou</s1>
<s2>15771 Athens</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<placeName>
<settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kolocouris, Antonios" sort="Kolocouris, Antonios" uniqKey="Kolocouris A" first="Antonios" last="Kolocouris">Antonios Kolocouris</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>School of Pharmacy, Department of Pharmaceutical Chemistry, University of Athens, Panepistimioupoli-Zografou</s1>
<s2>15771 Athens</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<placeName>
<settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kolocouris, Nicolas" sort="Kolocouris, Nicolas" uniqKey="Kolocouris N" first="Nicolas" last="Kolocouris">Nicolas Kolocouris</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>School of Pharmacy, Department of Pharmaceutical Chemistry, University of Athens, Panepistimioupoli-Zografou</s1>
<s2>15771 Athens</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<placeName>
<settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Fytas, George" sort="Fytas, George" uniqKey="Fytas G" first="George" last="Fytas">George Fytas</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>School of Pharmacy, Department of Pharmaceutical Chemistry, University of Athens, Panepistimioupoli-Zografou</s1>
<s2>15771 Athens</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<placeName>
<settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Foscolos, George B" sort="Foscolos, George B" uniqKey="Foscolos G" first="George B." last="Foscolos">George B. Foscolos</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>School of Pharmacy, Department of Pharmaceutical Chemistry, University of Athens, Panepistimioupoli-Zografou</s1>
<s2>15771 Athens</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<placeName>
<settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Neyts, Johan" sort="Neyts, Johan" uniqKey="Neyts J" first="Johan" last="Neyts">Johan Neyts</name>
<affiliation wicri:level="4">
<inist:fA14 i1="02">
<s1>Rega Institute for Medical Research, Katholieke Universiteit Leuven</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName>
<region type="province" nuts="2">Province du Brabant flamand</region>
<settlement type="city">Louvain</settlement>
</placeName>
<orgName type="university">Katholieke Universiteit Leuven</orgName>
</affiliation>
</author>
<author>
<name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
<affiliation wicri:level="4">
<inist:fA14 i1="02">
<s1>Rega Institute for Medical Research, Katholieke Universiteit Leuven</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName>
<region type="province" nuts="2">Province du Brabant flamand</region>
<settlement type="city">Louvain</settlement>
</placeName>
<orgName type="university">Katholieke Universiteit Leuven</orgName>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Bioorganic & medicinal chemistry letters</title>
<title level="j" type="abbreviated">Bioorg. med. chem. lett.</title>
<idno type="ISSN">0960-894X</idno>
<imprint>
<date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Bioorganic & medicinal chemistry letters</title>
<title level="j" type="abbreviated">Bioorg. med. chem. lett.</title>
<idno type="ISSN">0960-894X</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antiviral</term>
<term>Chemical synthesis</term>
<term>Conformational analysis</term>
<term>Diamine</term>
<term>In vitro</term>
<term>Influenza A virus</term>
<term>Modeling</term>
<term>Molecular dynamics method</term>
<term>Molecular model</term>
<term>Nitrogen heterocycle</term>
<term>Saturated compound</term>
<term>Structure activity relation</term>
<term>Tertiary amine</term>
<term>Tricyclic compound</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Relation structure activité</term>
<term>Synthèse chimique</term>
<term>Composé tricyclique</term>
<term>Composé saturé</term>
<term>Hétérocycle azote</term>
<term>Diamine</term>
<term>Amine tertiaire</term>
<term>Antiviral</term>
<term>Virus grippal A</term>
<term>In vitro</term>
<term>Modélisation</term>
<term>Modèle moléculaire</term>
<term>Méthode dynamique moléculaire</term>
<term>Analyse conformationnelle</term>
<term>Adamamtane dérivé</term>
<term>Pyrrolidine(3-[2-adamantyl]-1-[2-(dialkylamino)éthyl])</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The 3(2-adamantyl)pyrrolidines 8a g, 14 were synthesized and evaluated for activity against influenza A virus. The parent N H compound 14 was several times more active than amantadine against H
<sub>2</sub>
N
<sub>2</sub>
and H
<sub>3</sub>
N
<sub>2</sub>
influenza A virus. The combined use of NMR spectroscopy and computational chemistry showed that the conformation around the pyrrolidine-adamantyl carbon carbon bond is trans and the pyrrolidine heterocycle has an envelope conformation with C-2 out of the plane of the other ring atoms. N-Dialkylaminoethyl substitution of compound 14 resulted in the potent diamine analogues 8e,f,g. Interestingly, their lactam amine precursors were also active. Compounds 8e,f,g are the first adamantane derivatives, bearing two amine groups, reported to be active against influenza A virus.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0960-894X</s0>
</fA01>
<fA03 i2="1">
<s0>Bioorg. med. chem. lett.</s0>
</fA03>
<fA05>
<s2>11</s2>
</fA05>
<fA06>
<s2>16</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus : Identification of aminoadamantane derivatives bearing two pharmacophoric amine groups</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>STAMATIOU (George)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>KOLOCOURIS (Antonios)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>KOLOCOURIS (Nicolas)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>FYTAS (George)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>FOSCOLOS (George B.)</s1>
</fA11>
<fA11 i1="06" i2="1">
<s1>NEYTS (Johan)</s1>
</fA11>
<fA11 i1="07" i2="1">
<s1>DE CLERCQ (Erik)</s1>
</fA11>
<fA14 i1="01">
<s1>School of Pharmacy, Department of Pharmaceutical Chemistry, University of Athens, Panepistimioupoli-Zografou</s1>
<s2>15771 Athens</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Rega Institute for Medical Research, Katholieke Universiteit Leuven</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20>
<s1>2137-2142</s1>
</fA20>
<fA21>
<s1>2001</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>22446</s2>
<s5>354000095772720180</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2001 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA47 i1="01" i2="1">
<s0>01-0423706</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Bioorganic & medicinal chemistry letters</s0>
</fA64>
<fA66 i1="01">
<s0>GBR</s0>
</fA66>
<fA99>
<s0>1/2 p. ref. et notes</s0>
</fA99>
<fC01 i1="01" l="ENG">
<s0>The 3(2-adamantyl)pyrrolidines 8a g, 14 were synthesized and evaluated for activity against influenza A virus. The parent N H compound 14 was several times more active than amantadine against H
<sub>2</sub>
N
<sub>2</sub>
and H
<sub>3</sub>
N
<sub>2</sub>
influenza A virus. The combined use of NMR spectroscopy and computational chemistry showed that the conformation around the pyrrolidine-adamantyl carbon carbon bond is trans and the pyrrolidine heterocycle has an envelope conformation with C-2 out of the plane of the other ring atoms. N-Dialkylaminoethyl substitution of compound 14 resulted in the potent diamine analogues 8e,f,g. Interestingly, their lactam amine precursors were also active. Compounds 8e,f,g are the first adamantane derivatives, bearing two amine groups, reported to be active against influenza A virus.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Relation structure activité</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Structure activity relation</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Relación estructura actividad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Synthèse chimique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Chemical synthesis</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Síntesis química</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Composé tricyclique</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Tricyclic compound</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Compuesto tricíclico</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Composé saturé</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Saturated compound</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Compuesto saturado</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Hétérocycle azote</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Nitrogen heterocycle</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Heterociclo nitrógeno</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Diamine</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Diamine</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Diamina</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Amine tertiaire</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Tertiary amine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Amina terciaria</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Antiviral</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Antiviral</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Antiviral</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Virus grippal A</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>In vitro</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>In vitro</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>In vitro</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Modélisation</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Modeling</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Modelización</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE">
<s0>Modèle moléculaire</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG">
<s0>Molecular model</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA">
<s0>Modelo molecular</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE">
<s0>Méthode dynamique moléculaire</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG">
<s0>Molecular dynamics method</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA">
<s0>Método dinámico molecular</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE">
<s0>Analyse conformationnelle</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG">
<s0>Conformational analysis</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA">
<s0>Análisis conformacional</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE">
<s0>Adamamtane dérivé</s0>
<s2>NK</s2>
<s4>INC</s4>
<s5>62</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE">
<s0>Pyrrolidine(3-[2-adamantyl]-1-[2-(dialkylamino)éthyl])</s0>
<s2>NK</s2>
<s4>INC</s4>
<s5>63</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fN21>
<s1>295</s1>
</fN21>
</pA>
</standard>
</inist>
<affiliations>
<list>
<country>
<li>Belgique</li>
<li>Grèce</li>
</country>
<region>
<li>Attique (région)</li>
<li>Province du Brabant flamand</li>
</region>
<settlement>
<li>Athènes</li>
<li>Louvain</li>
</settlement>
<orgName>
<li>Katholieke Universiteit Leuven</li>
</orgName>
</list>
<tree>
<country name="Grèce">
<region name="Attique (région)">
<name sortKey="Stamatiou, George" sort="Stamatiou, George" uniqKey="Stamatiou G" first="George" last="Stamatiou">George Stamatiou</name>
</region>
<name sortKey="Foscolos, George B" sort="Foscolos, George B" uniqKey="Foscolos G" first="George B." last="Foscolos">George B. Foscolos</name>
<name sortKey="Fytas, George" sort="Fytas, George" uniqKey="Fytas G" first="George" last="Fytas">George Fytas</name>
<name sortKey="Kolocouris, Antonios" sort="Kolocouris, Antonios" uniqKey="Kolocouris A" first="Antonios" last="Kolocouris">Antonios Kolocouris</name>
<name sortKey="Kolocouris, Nicolas" sort="Kolocouris, Nicolas" uniqKey="Kolocouris N" first="Nicolas" last="Kolocouris">Nicolas Kolocouris</name>
</country>
<country name="Belgique">
<region name="Province du Brabant flamand">
<name sortKey="Neyts, Johan" sort="Neyts, Johan" uniqKey="Neyts J" first="Johan" last="Neyts">Johan Neyts</name>
</region>
<name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000070 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000070 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:01-0423706
   |texte=   Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus : Identification of aminoadamantane derivatives bearing two pharmacophoric amine groups
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021